Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 75

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 75
---
 to be applied on a prospective basis, although optional retrospective application is permitted. The Company plans to adopt the guidance for the fiscal year ending December 31, 2025. The Company expects ASU 2023-09 to require additional disclosures in the notes to its consolidated financial statements. The Company is currently evaluating the effects the adoption of this guidance will have on the consolidated financial statements.

10

ASU 2024-03, Disaggregation of Income Statement Expenses (Topic 220) - The new standard, issued in November 2024, requires additional disclosure in tabular format, about the nature of specific types of expense captions presented on the face of the income statement as well as disclosures about selling expenses. The new standard does not change the requirements for the presentation of expenses on the face of the income statement. The standard is effective with annual periods beginning after December 15, 2026. Early adoption and retrospective application are permitted. The Company plans to adopt the guidance for the fiscal year ending December 31, 2027. We expect ASU 2024-03 to require additional disclosures in the notes to our consolidated financial statements. The Company is currently evaluating the effects adoption of this guidance will have on the consolidated financial statements.

3. Disaggregated Revenues 

The following table provides information regarding total revenues (dollars in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(unaudited)(unaudited)Net product salesQelbree$77,547 $59,395 $142,292 $104,499 GOCOVRI36,660 31,703 67,349 58,265 APOKYN12,820 17,295 27,796 33,944 Trokendi XR11,193 17,086 23,994 33,075 Oxtellar XR11,637 29,516 21,835 56,459 ONAPGO1,604 — 1,604 — Other(1)6,534 7,543 15,113 14,757 Total net product sales157,995 162,538 299,983 300,999 Royalty, licensing and other revenues7,458 5,787 15,294 10,970 Total revenues$165,453 $168,325 $315,277 $311,969 ___________________________________________(